Tempest Therapeutics Inc (TPST)

Currency in USD
7.3900
-0.0700(-0.94%)
Closed·
After Hours
7.2900-0.1000(-1.35%)
·
TPST Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Earnings results expected tomorrow
Fair Value
Day's Range
7.22007.4600
52 wk Range
5.349528.3400
Key Statistics
Prev. Close
7.39
Open
7.4
Day's Range
7.22-7.46
52 wk Range
5.3495-28.34
Volume
34.79K
Average Volume (3m)
124.55K
1-Year Change
-59.1%
Book Value / Share
3.18
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
TPST Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
9.0000
Upside
+21.79%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

Tempest Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Buy
Moving Averages
Buy

Tempest Therapeutics Inc Company Profile

Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its clinical-stage lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd. for the development of Amezalpat into a global first-line randomized study. Tempest Therapeutics, Inc. is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc.

Compare TPST to Peers and Sector

Metrics to compare
TPST
Peers
Sector
Relationship
P/E Ratio
−0.7x−3.5x−0.5x
PEG Ratio
−0.030.010.00
Price/Book
2.7x2.9x2.6x
Price / LTM Sales
-10.2x3.3x
Upside (Analyst Target)
20.6%175.5%42.8%
Fair Value Upside
Unlock0.1%6.5%Unlock

Analyst Ratings

0 Buy
2 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Neutral

Analysts 12-Month Price Target:

Average 9.0000
(+21.79% Upside)

Earnings

Latest Release
May 13, 2025
EPS / Forecast
-3.16 / -0.26
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

TPST Income Statement

People Also Watch

264.75
AVAV
-1.19%
16.75
SRPT
-2.05%
6.32
REPL
+10.68%
0.98
KLTO
-2.00%
2.69
INMB
-5.95%

FAQ

What Stock Exchange Does Tempest Therapeutics Trade On?

Tempest Therapeutics is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Tempest Therapeutics?

The stock symbol for Tempest Therapeutics is "TPST."

What Is the Tempest Therapeutics Market Cap?

As of today, Tempest Therapeutics market cap is 30.21M.

What Is Tempest Therapeutics's Earnings Per Share (TTM)?

The Tempest Therapeutics EPS (TTM) is -17.38.

When Is the Next Tempest Therapeutics Earnings Date?

Tempest Therapeutics will release its next earnings report on 06 Aug 2025.

From a Technical Analysis Perspective, Is TPST a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has Tempest Therapeutics Stock Split?

Tempest Therapeutics has split 3 times.

How Many Employees Does Tempest Therapeutics Have?

Tempest Therapeutics has 24 employees.

What is the current trading status of Tempest Therapeutics (TPST)?

As of 06 Aug 2025, Tempest Therapeutics (TPST) is trading at a price of 7.39, with a previous close of 7.39. The stock has fluctuated within a day range of 7.22 to 7.46, while its 52-week range spans from 5.35 to 28.34.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.